Therefore, patients with therapy‐resistant HL have received anti‐PD1 therapy as well as brentuximab vedotin (anti‐CD30) in combination with chemo‐ and radiotherapies.21, 22. Here, TNFRSF8 is linked to Hodgkins lymphoma.